Details for New Drug Application (NDA): 022465
✉ Email this page to a colleague
The generic ingredient in VOTRIENT is pazopanib hydrochloride. There are five drug master file entries for this compound. Seven suppliers are listed for this compound. Additional details are available on the pazopanib hydrochloride profile page.
Summary for 022465
Tradename: | VOTRIENT |
Applicant: | Novartis |
Ingredient: | pazopanib hydrochloride |
Patents: | 0 |
Suppliers and Packaging for NDA: 022465
Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
---|---|---|---|---|---|---|---|---|
VOTRIENT | pazopanib hydrochloride | TABLET;ORAL | 022465 | NDA | Novartis Pharmaceuticals Corporation | 0078-1077 | 0078-1077-66 | 120 TABLET, FILM COATED in 1 BOTTLE (0078-1077-66) |
Profile for product number 001
Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET;ORAL | Strength | EQ 200MG BASE | ||||
Approval Date: | Oct 19, 2009 | TE: | AB | RLD: | Yes |
Profile for product number 002
Active Rx/OTC/Discontinued: | DISCN | Dosage: | TABLET;ORAL | Strength | EQ 400MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | ||||
Approval Date: | Oct 19, 2009 | TE: | RLD: | Yes |
Expired US Patents for NDA 022465
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Novartis | VOTRIENT | pazopanib hydrochloride | TABLET;ORAL | 022465-001 | Oct 19, 2009 | 7,105,530 | ⤷ Subscribe |
Novartis | VOTRIENT | pazopanib hydrochloride | TABLET;ORAL | 022465-002 | Oct 19, 2009 | 8,114,885 | ⤷ Subscribe |
Novartis | VOTRIENT | pazopanib hydrochloride | TABLET;ORAL | 022465-002 | Oct 19, 2009 | 7,262,203 | ⤷ Subscribe |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Complete Access Available with Subscription